全球蛋白质治疗市场规模、份额、成长分析、按产品类型、按应用、按治疗领域 - 行业预测，2024-2031 年

2022年全球蛋白质治疗市场规模为65.7亿美元，从2023年的69.6亿美元成长到2031年的111亿美元，在预测期间（2024-2031年）预计复合年增长率为6%。

由于生物製药领域的不断扩大和慢性病盛行率的上升，蛋白质治疗市场正在经历显着增长。单株抗体、胰岛素和疫苗等蛋白质治疗药物在各种疾病的治疗中继续发挥重要作用。生物技术的进步以及基于蛋白质的创新配方的出现，为市场扩张做出了重大贡献。此外，儘管存在高製造成本和监管障碍等挑战，但个人化医疗和标靶治疗策略的日益采用也推动了需求。虽然北美仍然占据主导地位，但在医疗基础设施改善和患者数量迅速增加的推动下，亚太地区正在迅速崛起。主要趋势包括寻找新的治疗标靶以及将先进技术整合到蛋白质治疗开发中。

目录

执行摘要

• 市场概况
• 命运之轮

调查方法

• 资讯采购
• 次要和主要资料来源
• 市场规模估算
• 市场假设与限制

母市场分析

• 市场概况
• 市场规模
• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务

主要市场考察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• Start-Ups分析
• 原料分析
• 创新矩阵
• 研发线产品分析
• 总体经济指标
• 主要投资分析
• 关键成功因素
• 竞争程度

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 监管环境
• 波特的分析
• 对未来中断的特殊考虑

全球蛋白质疗法市场：按产品类型

• 市场概况
• 单株抗体
• 胰岛素
• 疫苗
• 生长激素
• 凝血因子
• 酵素替代疗法

全球蛋白质治疗市场：依应用分类

• 市场概况
• 肿瘤学
• 血液学
• 免疫学
• 代谢紊乱
• 心血管疾病
• 其他的

全球蛋白质治疗市场：按治疗领域

• 市场概况
• 癌症
• 糖尿病
• 感染疾病
• 自体免疫疾病
• 遗传疾病
• 其他的

全球蛋白质治疗市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2021年）
• 主要市场参与者所采取的策略
• 关键成功策略
• 近期市集活动
• 主要企业市场占有率（2021年）

主要企业简介

• Amgen Inc.（US）
• AbbVie Inc.（US）
• Roche Diagnostics（Switzerland）
• Eli Lilly and Company（US）
• Johnson & Johnson（US）
• Pfizer Inc.（US）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Novo Nordisk A/S（Denmark）
• Merck & Co., Inc.（US）
• Celgene Corporation（US）
• GlaxoSmithKline PLC（UK）
• Gilead Sciences, Inc.（US）
• Biogen Inc.（US）
• AstraZeneca PLC（UK）
• Takeda Pharmaceutical Company Limited（Japan）
• Abbott Laboratories（US）
• Bayer AG（Germany）
• Alexion Pharmaceuticals Inc.（US）
• Novartis AG（Switzerland）
• Sanofi（France）

Global Protein Therapeutics Market size was valued at USD 6.57 billion in 2022 and is poised to grow from USD 6.96 billion in 2023 to USD 11.10 billion by 2031, growing at a CAGR of 6% during the forecast period (2024-2031).

The Protein Therapeutics market is experiencing significant growth attributed to the expanding realm of biopharmaceuticals and the rising prevalence of chronic illnesses. Monoclonal antibodies, insulin, and vaccines, among other protein therapeutics, continue to serve as crucial components in treating various medical conditions. Technological advancements in biotechnology, alongside the emergence of innovative protein-based formulations, contribute significantly to market expansion. Moreover, the increasing adoption of personalized medicine and targeted treatment strategies drives demand, despite challenges such as high production costs and regulatory hurdles. While North America remains dominant, the Asia-Pacific region is rapidly emerging, propelled by improved healthcare infrastructure and burgeoning patient populations. Key trends include the exploration of novel therapeutic targets and the integration of advanced technologies into protein therapy development.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Protein Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Protein Therapeutics Market Segmental Analysis

The global Protein Therapeutics market is segmented into four major segments i.e. by Product Type, Application, Therapeutic Area, and region. Based on Type, it is divided into Monoclonal Antibodies, Insulin, Vaccines, Growth Hormones, Blood Clotting Factors, Enzyme Replacement Therapies. Based on Application, it is bifurcated as Oncology, Hematology, Immunology, Metabolic Disorders, Cardiovascular Disorders, Others. Based on Therapeutic Area it is segregated into Cancer, Diabetes, Infectious Diseases, Autoimmune Disorders, Genetic Disorders, and Others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Drivers of the Global Protein Therapeutics Market

The increasing incidence of chronic ailments and intricate medical conditions underscores the significance of protein-based therapies, offering tailored and efficient solutions. The adaptability of protein therapeutics, encompassing monoclonal antibodies and other biologics, enables precise interventions across diverse therapeutic domains such as oncology, immunology, and metabolic disorders. Moreover, advancements in biotechnology and genetic engineering have paved the way for the creation of innovative and more potent protein therapeutics. As the demand for personalized medicine rises and the need for biopharmaceuticals with reduced side effects grows, there is a burgeoning inclination towards the adoption of protein-based treatments.

Restraints in the Global Protein Therapeutics Market

One of the main obstacles in the marketplace is the high cost linked with the development, production, and introduction of protein-based therapies. The intricate manufacturing processes and the requirement for sophisticated technologies contribute to inflated expenses, restricting accessibility, particularly in less affluent regions. Moreover, regulatory intricacies and rigorous approval procedures create hurdles, prolonging the time-to-market for protein therapeutics. Concerns regarding immunogenicity, wherein the patient's immune system may react to the therapeutic protein, further complicate matters.

Market Trends of the Global Protein Therapeutics Market

There is a noticeable shift towards personalized treatment in healthcare, particularly evident in the development of targeted protein therapeutics customized to individual patient characteristics. This trend is supported by advancements in next-generation biologics like antibody-drug conjugates and bispecific antibodies, offering more potent and adaptable therapeutic options. Additionally, advancements in protein engineering are enabling the creation of novel and optimized protein structures, thereby enhancing therapeutic effectiveness. The exploration of alternative delivery routes such as subcutaneous and oral administration is becoming increasingly popular, offering improved patient convenience.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Protein Therapeutics Market by Product Type

• Market Overview
• Monoclonal Antibodies
• Insulin
• Vaccines
• Growth Hormones
• Blood Clotting Factors
• Enzyme Replacement Therapies

Global Protein Therapeutics Market by Application

• Market Overview
• Oncology
• Hematology
• Immunology
• Metabolic Disorders
• Cardiovascular Disorders
• Others

Global Protein Therapeutics Market by Therapeutic Area

• Market Overview
• Cancer
• Diabetes
• Infectious Diseases
• Autoimmune Disorders
• Genetic Disorders
• Others

Global Protein Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments